# Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

> **NCT05183854** · PHASE2 · RECRUITING · sponsor: **University of Utah** · enrollment: 61 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** Pneumococcal 20-valent Conjugate Vaccine
- **BIOLOGICAL:** Pneumococcal Polyvalent Vaccine

## Key facts

- **NCT ID:** NCT05183854
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-31
- **Primary completion:** 2027-03
- **Final completion:** 2028-06
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183854, "Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05183854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*